Provided by Tiger Fintech (Singapore) Pte. Ltd.

Humacyte, Inc.

3.09
+0.13004.39%
Volume:2.62M
Turnover:7.86M
Market Cap:397.59M
PE:-2.28
High:3.11
Open:2.97
Low:2.88
Close:2.96
Loading ...

Humacyte announces planned IND filing in 2025 for sdATEV for CABG

TIPRANKS
·
21 Jan

Humacyte Announces Planned Ind Filing in 2025 to Support First-in-Human Clinical Study of Small-Diameter Atev™ for Coronary Artery Bypass Grafting

THOMSON REUTERS
·
21 Jan

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

GlobeNewswire
·
21 Jan

HUMA Lawsuit Alert! Class Action Against Humacyte, Inc.

TIPRANKS
·
16 Jan

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
13 Jan

Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (Acellular Tissue Engineered Vessel-Tyod) for Extremity Vascular Trauma

THOMSON REUTERS
·
13 Jan

Humacyte price target raised to $17 from $15 at Benchmark

TipRanks
·
24 Dec 2024

High Growth Tech Stocks to Watch in December 2024

Simply Wall St.
·
24 Dec 2024

Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Ligand Pharma (LGND)

TIPRANKS
·
23 Dec 2024

Humacyte Inc : Benchmark Raises Target Price to $17 From $15

THOMSON REUTERS
·
23 Dec 2024

Top Midday Gainers

MT Newswires Live
·
21 Dec 2024

BTIG Sticks to Their Buy Rating for Humacyte (HUMA)

TIPRANKS
·
21 Dec 2024

BRIEF-FDA Approves First Acellular Tissue Engineered Vessel To Treat Vascular Trauma In Extremities

Reuters
·
21 Dec 2024

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
20 Dec 2024

Stock Track | Humacyte Soars Over 50% as FDA Approves SYMVESS for Vascular Trauma Treatment

Stock Track
·
20 Dec 2024

Humacyte Shares up 84.2% After FDA Approves Blood Vessel Implant

THOMSON REUTERS
·
20 Dec 2024